Harsh Sheth1, Samir Bagasrawala2, Mita Shah3, Rais Ansari2, A Olithselvan4, Muffazal Lakdawala2. 1. Institute of Minimally Invasive Surgical Sciences and Research, Saifee Hospital, 15/17 Maharshi Karve Marg, Opera House, Mumbai, 400004, India. harsh86sheth@gmail.com. 2. Institute of Minimally Invasive Surgical Sciences and Research, Saifee Hospital, 15/17 Maharshi Karve Marg, Opera House, Mumbai, 400004, India. 3. Department of Pathology, Saifee Hospital, 15/17 Maharshi Karve Marg, Opera House, Mumbai, 400004, India. 4. Department of Hepatology, Yashoda Hospital, S. P Road, Secunderabad, 500003, India.
Abstract
BACKGROUND: The prevalence of NAFLD increases in obese diabetics. Accurate diagnosis of NAFLD requires invasive liver biopsies, which is costly, and time consuming and labor intensive. Currently, there is a lack of non-invasive diagnostic methods to identify those with NASH, in obese Indians. OBJECTIVES: To develop an accurate non-invasive scoring system using clinical and biochemical parameters to predict the risk of developing non-alcoholic steatohepatitis (NASH). METHODS: Clinical and biochemical parameters were recorded pre-operatively from 290 patients who were posted for bariatric/metabolic surgery, between September 2017 and October 2018 and compared with the result of intra-operative liver biopsy NAFLD activity scores (NAS). RESULTS: The mean weight and BMI of the patients were 120.3 ± 24.6 and 45.5 ± 7.8 respectively. In the final histopathological examination, 196/290 (67.6%) had simple steatosis, 92/290 (31.7%) had NASH, and 2/290 (0.007%) had cirrhosis. Binary logistic regression analysis of multiple independent predictors yielded five independent factors that were statistically significant (HbA1c, AST, ALT, liver span on USG, and serum triglycerides). These were used to create a scoring system, with a range of scores from 0 to 6, with maximum predictability at a score of 6. Patients with scores of ≧ 3 were at high risk of NASH diagnosis. The sensitivity of this scoring system was 85.87% and diagnostic accuracy was 75.35%. CONCLUSIONS: Our study not only confirms the significant association of NAFLD with obesity but also outlines a simple non-invasive scoring system to identify obese individuals at high risk for NASH.
BACKGROUND: The prevalence of NAFLD increases in obese diabetics. Accurate diagnosis of NAFLD requires invasive liver biopsies, which is costly, and time consuming and labor intensive. Currently, there is a lack of non-invasive diagnostic methods to identify those with NASH, in obese Indians. OBJECTIVES: To develop an accurate non-invasive scoring system using clinical and biochemical parameters to predict the risk of developing non-alcoholic steatohepatitis (NASH). METHODS: Clinical and biochemical parameters were recorded pre-operatively from 290 patients who were posted for bariatric/metabolic surgery, between September 2017 and October 2018 and compared with the result of intra-operative liver biopsy NAFLD activity scores (NAS). RESULTS: The mean weight and BMI of the patients were 120.3 ± 24.6 and 45.5 ± 7.8 respectively. In the final histopathological examination, 196/290 (67.6%) had simple steatosis, 92/290 (31.7%) had NASH, and 2/290 (0.007%) had cirrhosis. Binary logistic regression analysis of multiple independent predictors yielded five independent factors that were statistically significant (HbA1c, AST, ALT, liver span on USG, and serum triglycerides). These were used to create a scoring system, with a range of scores from 0 to 6, with maximum predictability at a score of 6. Patients with scores of ≧ 3 were at high risk of NASH diagnosis. The sensitivity of this scoring system was 85.87% and diagnostic accuracy was 75.35%. CONCLUSIONS: Our study not only confirms the significant association of NAFLD with obesity but also outlines a simple non-invasive scoring system to identify obese individuals at high risk for NASH.
Authors: F Angelico; M Del Ben; R Conti; S Francioso; K Feole; S Fiorello; M G Cavallo; B Zalunardo; F Lirussi; C Alessandri; F Violi Journal: J Clin Endocrinol Metab Date: 2004-12-14 Impact factor: 5.958
Authors: David E Kelley; Therese M McKolanis; Refaat A F Hegazi; Lewis H Kuller; Satish C Kalhan Journal: Am J Physiol Endocrinol Metab Date: 2003-10 Impact factor: 4.310
Authors: Fernanda Bu Pulzi; Raul Cisternas; Murilo R Melo; Cristiane Mf Ribeiro; Carlos A Malheiros; João E Salles Journal: Diabetol Metab Syndr Date: 2011-02-23 Impact factor: 3.320
Authors: Viera Kupčová; Michaela Fedelešová; Jozef Bulas; Petra Kozmonová; Ladislav Turecký Journal: Int J Environ Res Public Health Date: 2019-09-24 Impact factor: 3.390